Sign in

CIK 0001668243

  • Non-accelerated filer
  • Smaller reporting company

UroGen Pharma Ltd.

Sign in to watch
Ticker
URGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Israel
Entity type
Operating
Phone
+972 97707601
Business address
9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
  1. 4 Exercise or conversion Director acquired 1,030 shares (option exercise)
  2. 4 Open-market sale Chief Medical Officer sold 259 shares at $7.81 ($2,023)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale Chief Medical Officer sold 254 shares at $6.62 ($1,681)
  9. 4 Derivatives Options or other derivatives
  10. 3 Insider Initial Statement of Ownership
  11. 4 Open-market sale General Counsel sold 414 shares at $7.58 ($3,138)
  12. 4 Open-market sale Chief Financial Officer sold 331 shares at $7.58 ($2,509)
  13. 4 Open-market sale Chief Medical Officer sold 1,374 shares at $7.58 ($10,415)
  14. 4 Open-market sale Chief Executive Officer sold 8,195 shares at $7.58 ($62,118)
  15. 4 Open-market sale Chief Medical Officer sold 111 shares at $8.09 ($898)
  16. 4 Open-market sale Chief Executive Officer sold 46,968 shares at $9.15 ($429,757)
  17. 4 Open-market sale General Counsel sold 3,803 shares at $12.03 ($45,750)
  18. 4 Open-market sale Chief Financial Officer sold 2,587 shares at $12.03 ($31,122)
  19. 4 Open-market buy Chief Medical Officer bought 160 shares at $13.10 ($2,096)
  20. 4 Open-market sale Chief Medical Officer sold 258 shares at $17.16 ($4,427)

Page 6 of 12 · 233 filings